We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Point of Care Tests to Help Reduce Overuse of Antibiotics

By LabMedica International staff writers
Posted on 27 Jan 2025
Print article
Image: The trials have the potential to significantly improve the safe use of antibiotics and reduce AMR (Photo courtesy of Deakin University)
Image: The trials have the potential to significantly improve the safe use of antibiotics and reduce AMR (Photo courtesy of Deakin University)

The misuse of antibiotics—such as taking them unnecessarily, for too long, or in incorrect doses—leads to antimicrobial resistance (AMR), making infections harder to treat and increasing the risks of severe illness and death. AMR causes 700,000 global deaths annually, and many people either expect antibiotics from doctors or misuse them by not following prescribed dosages. Doctors face challenges in prescribing antibiotics due to diagnostic uncertainty, patient self-diagnosis, and limited resources. Now, two new tests for bacterial infections could help reduce the overuse of antibiotics for common respiratory illnesses.

Researchers at Deakin University (Victoria, Australia) are leading trials of the two new tests involving a simple finger prick or throat swab that provide immediate results to distinguish between bacterial and viral infections. This can enable more accurate diagnoses and targeted treatments, potentially reducing unnecessary antibiotic prescriptions. In international trials conducted earlier, the finger prick test has already shown promise, while early results from the latest trial indicate a reduction of antibiotic use by up to 30%. This test can help doctors determine if common respiratory infections are bacterial or viral, ensuring antibiotics are only prescribed when necessary.

The second test, a throat swab, allows doctors to quickly identify if a sore throat is caused by Strep A bacteria, a common source of throat infections. Despite Strep A being responsible for only 15 to 20% of sore throats, antibiotics are often overprescribed in 70% of cases. Proper diagnosis and early treatment are critical, especially in children, as Strep A can lead to severe complications like rheumatic heart disease. This throat swab test will optimize antibiotic treatment for Strep A. A feasibility trial conducted in 2024 with 200 patients across five clinics, followed by a pilot trial in 2025 with 400 patients, aims to further assess the test’s effectiveness in reducing antibiotic overuse. Both these trials hold the potential to significantly improve the responsible use of antibiotics.

“This work is trying to improve the capacity of GPs and community pharmacists with point-of-care diagnostic testing services,” said Dr. Sajal Saha, Research Fellow in the Centre for Innovation in Infectious Disease and Immunology Research. “This will help prescribers better understand the severity of infections or confirm bacterial infections for some respiratory infections during patient consultations and prescribe antibiotics accordingly.”

Related Links:
Deakin University

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.